|
1996
|
Foundation as a joint venture between Boehringer Mannheim and Science Park Raf to provide cell therapy services
|
|
1999
|
Acquisition of Boehringer Mannheim by Roche, which then sells its equity stake to EDCP venture capital fund
|
|
2000
|
Evolution of business model: from service company to biopharmaceutical product company
|
|
2002
|
Acquisition and incorporation of Genera S.p.A., the research company of the San Raffaele Institute
|
|
2004
|
Entrance of three major Italian private investors: Fininvest, Herule Finance (now H-Equity S.r.l.) and La Leonardo Finanziaria (now Delfin S. ŕ r.l.) as new shareholders, generating a capital increase of 20 million Euro
|
|
2006
|
Capital increase of 16 million Euro
|
|
2007
|
Capital increase of 10 million Euro
|
|
2008
|
IPO of 25% of shares, resulting in 56 million Euro gross proceeds. Shares traded on the Milan Stock Exchange (MTA, standard segment) since March 5, 2008. Total outstanding shares: 105,207,808 (100% ordinary shares with no par value)
|
2010
|
Share capital increase (1 newly issued share for each outstanding share), resulting in 58 million Euro gross proceeds. Total outstanding shares: 210,415,616 (100% ordinary shares with no par value) |
| |
|
| |
|
;)